Source 1review2022Chemical Society Reviews
Toolkit/proteolysis targeting chimeras
proteolysis targeting chimeras
Also known as: PROTACs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
The ubiquitin-proteasome pathway can be hijacked toward non-native neo-substrate proteins using proteolysis targeting chimeras (PROTACs), bifunctional molecules designed to simultaneously bind to an E3 ligase and a target protein to induce target ubiquitination and degradation.
Usefulness & Problems
No literature-backed usefulness or problem-fit explainer has been materialized for this record yet.
Published Workflows
Objective: Discover and optimize small-molecule ligands for the VHL E3 ligase, then implement them into potent PROTAC degraders and inhibitor applications.
Why it works: The review states that high-quality E3 ligase ligands with good binding affinity are fundamental enabling components for PROTAC development, so ligand discovery precedes degrader implementation.
VHL bindingdisruption or modulation of VHL substrate recognitioninduced target ubiquitination and degradation via bifunctional recruitmentstructure-based designrational design of bifunctional degraders
Stages
- 1.Structure-based design of VHL ligands(library_design)
The review identifies high-quality E3 ligase ligands as fundamental starting points for PROTAC development.
Selection: Design ligands that bind VHL with good binding affinity.
- 2.Application of VHL ligands as inhibitors(functional_characterization)
The review explicitly covers VHL ligands as inhibitors, indicating a functional use case beyond degrader recruitment.
Selection: Assess VHL ligands for inhibitor use in their own right.
- 3.Implementation of VHL ligands into rationally designed PROTAC degraders(functional_characterization)
Once suitable VHL ligands are available, they can be implemented into PROTACs to hijack the ubiquitin-proteasome pathway toward chosen targets.
Selection: Use VHL ligands as E3-recruiting components in bifunctional degraders of target proteins.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A composed arrangement of multiple parts that instantiates one or more mechanisms.
Mechanisms
Degradatione3 ligase recruitmentinduced proximityproteasomal degradationtarget ubiquitinationTechniques
Computational DesignTarget processes
degradationInput: Chemical
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Source 2review2026MED
Ranked Claims
Induced-proximity degrader modalities expand the druggable proteome and transcriptome.
These induced-proximity modalities exploit endogenous degradation or regulatory pathways using chemically engineered bifunctional or monofunctional small molecules.
The review identifies five major induced-proximity modalities: PROTACs, molecular glues, LYTACs, AUTACs and related tethering strategies, and RIBOTACs.
High-quality small-molecule ligands with good binding affinity for E3 ligases are fundamental for PROTAC development.
The availability of high-quality small-molecule ligands with good binding affinity for E3 ligases is fundamental for PROTAC development.
A lack of good E3 ligase ligands was an initial stumbling block for development of the PROTAC field.
Lack of good E3 ligase ligands as starting points to develop PROTAC degraders was initially a stumbling block to the development of the field.
PROTACs are bifunctional molecules that simultaneously bind an E3 ligase and a target protein to induce target ubiquitination and degradation.
proteolysis targeting chimeras (PROTACs), bifunctional molecules designed to simultaneously bind to an E3 ligase and a target protein to induce target ubiquitination and degradation
Approval Evidence
3 sources7 linked approval claimsfirst-pass slug proteolysis-targeting-chimeras
Between 2020 and 2025, major progress has been achieved across five modalities: proteolysis-targeting chimeras (PROTACs)... Each exploits endogenous degradation or regulatory pathways using chemically engineered bifunctional or monofunctional small molecules.
Source:
The ubiquitin-proteasome pathway can be hijacked toward non-native neo-substrate proteins using proteolysis targeting chimeras (PROTACs), bifunctional molecules designed to simultaneously bind to an E3 ligase and a target protein to induce target ubiquitination and degradation.
Source:
Proteolysis-targeting chimeras (PROTACs) in cancer therapy
Source:
capability summarysupports
Induced-proximity degrader modalities expand the druggable proteome and transcriptome.
Source:
mechanism summarysupports
These induced-proximity modalities exploit endogenous degradation or regulatory pathways using chemically engineered bifunctional or monofunctional small molecules.
Source:
modality scopesupports
The review identifies five major induced-proximity modalities: PROTACs, molecular glues, LYTACs, AUTACs and related tethering strategies, and RIBOTACs.
Source:
application scopesupports
PROTACs are discussed as a modality in cancer therapy.
Source:
enabling factorsupports
High-quality small-molecule ligands with good binding affinity for E3 ligases are fundamental for PROTAC development.
The availability of high-quality small-molecule ligands with good binding affinity for E3 ligases is fundamental for PROTAC development.
Source:
historical bottlenecksupports
A lack of good E3 ligase ligands was an initial stumbling block for development of the PROTAC field.
Lack of good E3 ligase ligands as starting points to develop PROTAC degraders was initially a stumbling block to the development of the field.
Source:
mechanistic summarysupports
PROTACs are bifunctional molecules that simultaneously bind an E3 ligase and a target protein to induce target ubiquitination and degradation.
proteolysis targeting chimeras (PROTACs), bifunctional molecules designed to simultaneously bind to an E3 ligase and a target protein to induce target ubiquitination and degradation
Source:
Comparisons
No literature-backed comparison notes have been materialized for this record yet.
Ranked Citations
- 1.
- 2.